Study Summary
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive advanced malignancies.
Want to learn more about this trial?
Request More InfoInterventions
ACTR T Cell ProductBIOLOGICAL
Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
TrastuzumabDRUG
monoclonal antibody targeting HER2
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Yale Smilow Cancer Hospital | New Haven | Connecticut | United States |
| Miami University Cancer Center | Miami | Florida | United States |
| The Ohio State University | Columbus | Ohio | United States |
| Sarah Cannon Research Institute/Tennessee Oncology, PLLC | Nashville | Tennessee | United States |
| Baylor Scott & White Medical Center | Dallas | Texas | United States |
| MD Anderson Cancer Center | Houston | Texas | United States |